Rexahn Reports Positive Preliminary Findings In ZoraxelTM Clinical Trial To Treat Erectile Dysfunction
Rexahn Pharmaceuticals, Inc. (NYSE Amex RNN) announced preliminary results for its sexual dysfunction drug candidate, Zoraxel™, from a Phase IIa clinical study for the treatment of erectile dysfunction (ED). The double blind, randomized, placebocontrolled, dose ranging study found that human subjects treated with Zoraxel demonstrated improved erectile function as measured by changes over the International [...]